- $55.38m
- $53.65m
Annual income statement for Jupiter Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.13 | 0.638 | 0.233 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.05 | 4.63 | 4.71 | 4.76 | 2.23 |
| Operating Profit | -1.93 | -3.99 | -4.48 | -4.76 | -2.23 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.65 | -4.2 | -4.96 | -4.78 | -2.44 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.65 | -4.2 | -4.96 | -4.78 | -2.44 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.65 | -4.2 | -4.96 | -4.78 | -2.44 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.65 | -4.2 | -4.96 | -4.78 | -2.44 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.096 | -0.125 | -0.119 | -0.118 | -0.115 |
| Dividends per Share |